VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 17,000 Charles River Laboratories International, Inc. $CRL

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 17,000 shares of the medical research company’s stock, valued at approximately $3,855,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Continuum Advisory LLC bought a new stake in Charles River Laboratories International during the second quarter worth $30,000. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the 4th quarter valued at $42,000. Sfam LLC purchased a new position in Charles River Laboratories International during the 4th quarter worth $43,000. Geneos Wealth Management Inc. boosted its holdings in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth $46,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 0.9%

Shares of CRL stock opened at $278.36 on Thursday. The company has a 50 day moving average of $258.38 and a 200-day moving average of $204.34. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $303.30. The firm has a market cap of $13.29 billion, a P/E ratio of -57.39, a PEG ratio of 2.75 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the business earned $3.12 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CRL shares. Robert W. Baird set a $291.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, August 6th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Morgan Stanley lifted their price target on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Mizuho set a $264.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Insider Activity at Charles River Laboratories International

In other news, CAO Michael Knell sold 6,645 shares of Charles River Laboratories International stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total value of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at approximately $3,086,023.76. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Victoria Creamer sold 4,179 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 165,990 shares of company stock worth $42,606,388 in the last three months. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.